• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Giiant Pharma raises $11M for drug delivery platform for gastroenterology

May 21, 2021 By Sean Whooley

GIIANT Pharma_Logo_RGB_nonameGiiant Pharma announced today that it closed a $11 million seed financing round for its drug delivery technology platform.

Montreal-based Giiant develops the Precision Delivery technology platform, which originated from the work of former Merck Frosst scientists, according to a news release. The company designs gut-restricted, tissue-specific, small-molecule drug therapeutics to be delivered through the platform.

“Precision Delivery is an exciting concept which has the potential to transform the field of gastroenterology,” Giiant Pharma CEO Maxime Ranger said in the release.

The company identified the orally administered, colon-specific PDE4 inhibitor prodrug GT-2108 as a lead candidate for treating inflammatory bowel diseases (IBD). GT-2108 has potent anti-inflammatory properties and its prodrug format requires activation by the gut microbiota before the drug can elicit its effects, Giiant said.

With the $11 million in funds raised, Giiant initiated the investigational new drug-enabling preclinical program with GT-2108 for treating moderate-to-severe ulcerative colitis. The company is also discussing the potential expansion of its pipeline for treating gastrointestinal disease.

“With a unique ability to deliver an active PDE4 inhibitor to the site of inflammation in the gut, we expect limited systemic exposure and a safer profile,” Giiant Pharma co-founder & chief development officer Dr. Elizabeth Kwong said.

Funds in the seed round came from co-leaders Amplitude Ventures and Genesys Capital, while Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, Anges Québec and other angel investors contributed.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Preclinical Trials Tagged With: Giiant Pharma

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS